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Summary. Tubular aggregates (TAs) are aggregates of
densely packed tubules in human skeletal muscle fibers
with particular histochemical and ultrastructural features
that most probably arise from the sarcoplasmic
reticulum. Some studies have shown an additional
mitochondrial origin of TAs. We studied the
histopathological spectrum and clinical features in a
large cohort of patients with TAs in their muscle biopsy
(106 biopsies), derived from our muscle biopsy archive
(15,412 biopsies in total). In particular, we examined
light microscopic, enzyme histochemical, immunohisto-
chemical and ultrastructural features in the muscle
biopsies, as well as the patients’ clinical data. We found
TAs in 0.5% of all muscle biopsies. Based on the size of
TAs, we identified two sub-groups: (1) myopathies with
large TAs (29 biopsies) in type 2 fibers and sometimes
also in type 1 fibers, absence of any other associated
disorder, and a familial history in half of the cases, and
(2) myopathies with small TAs (77 biopsies), exclusively
in type 2 fibers, presence of another associated disease in
the majority of patients and mostly no familial history. In
the sub-group with large TAs, we observed a high
variability of ultrastructural changes. The most frequent
clinical symptom in both groups was limb muscle
weakness. No significant differences in clinical
presentation, age at onset or disease duration at the time
of biopsy were found between the two groups. In
conclusion, myopathies with TAs can be sub-divided
into a group with large TAs, probably corresponding to
the so-called primary TA myopathies, and into a group
with small TAs as a feature of another underlying
condition.
Key words: Tubular aggregate myopathy, TAM,
Skeletal muscle, Ultrastructure, Sarcoplasmic reticulum 
Introduction
In 1964, Engel described aggregates in human
skeletal muscle fibers with certain histochemical
features, such as an intense reaction for reduced
nicotinamide-adenine-dinucleotide dehydrogenase
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(NADH), staining by modified Gomori’s trichrome (GT)
and absence of succinate dehydrogenase (SDH) (Engel,
1964). The aggregates were named tubular aggregates
(TAs) after additional ultrastructural analysis was
performed in 1970 (Engel et al., 1970). TAs typically
appear as a group of tubules oriented in parallel, with
diameters ranging from 40-200 nm at electron
microscopic (EM) level, however, a large variety of
ultrastructural features has been described (Engel et al.,
1970; Schröder and Becker, 1972; Cameron et al., 1992;
Pavlovicová et al., 2003). A number of different TA
classifications have been proposed based on
ultrastructural findings (Schröder and Becker, 1972;
Cameron et al., 1992; Pavlovicová et al., 2003). The
derivation of TAs from the sarcoplasmic reticulum (SR)
was shown by EM and immunohistochemical studies
(Engel et al., 1970; Pierobon-Bormioli et al., 1985;
Salviati et al., 1985; Chevessier et al., 2005). Other
enzyme histochemical and immunohistochemical studies
suggest that TAs may arise from both SR and
mitochondria (Lewis et al., 1971; Rosenberg et al., 1985;
Novotova et al., 2002).
Familial and sporadic cases of tubular aggregate
myopathies (TAM) with TAs as the predominant
histopathological finding have been reported (Engel et
al., 1970; Lewis et al., 1971; Schröder and Becker, 1972;
Dobkin and Verity, 1978; Sipilä et al., 1979; Rohkamm
et al., 1983; Pierobon-Bormioli, 1985; Rosenberg et al.,
1985; Salviati et al., 1985; Cameron et al., 1992; Sieb et
al., 1996; Furui et al, 1997; Martin et al., 1997; Alonso-
Losada et al., 1998; Müller et al., 2001; Jacques et al.,
2002; Sharizaila et al., 2004; Chevessier et al., 2005;
Ghosh et al., 2010; Guergueltcheva et al., 2011;
Senderek et al., 2011). For most cases of familial TAM,
an autosomal-dominant inheritance has been suggested
(Rohkamm et al., 1983; Cameron et al., 1992; Martin et
al., 1997; Müller et al., 2001; Shahrizaila et al., 2004).
Furthermore, various, occasional associations of TAs
with other hereditary myopathies, such as myotonic
myopathy (Schröder and Adams, 1968; Schröder and
Becker, 1972; Rosenberg et al., 1985), congenital
myasthenic syndromes (Guergueltcheva et al., 2011;
Belaya et al., 2012; Huh et al., 2012) or acquired
systemic conditions such as alcoholic myopathy
(Gullotta and Helpap, 1975; del Villar Negro et al.,
1982) are known. 
Major clinical phenotypes of myopathies with TAs
involve exertional myalgia, muscle cramps and stiffness,
with or without weakness (Pierobon-Bormioli, 1985;
Rosenberg et al., 1985; Martin et al., 1997; Müller et al.,
2001), slowly progressive proximal weakness
(Rohkamm et al., 1983; Alonso-Losada et al., 1998),
limb-girdle myasthenia with predominant fatigability
(Dobkin and Verity, 1978; Sieb et al., 1996; Furui et al.,
1997; Guergueltcheva et al., 2011; Senderek et al., 2011)
and periodic paralysis (Engel et al., 1970; Jurkat-Rott et
al., 2000; Luan et al., 2009).
In the present study, we characterized the
histopathological spectrum and clinical features in a
large cohort of 93 index patients (i.e. unrelated patients)
with TAs in their muscle biopsy (106 biopsies in total),
in order to identify morphological-clinical sub-groups
that might be helpful in orienting further diagnosis.
Materials and methods
Biopsy retrieval and selection
We screened the database of the muscle tissue
archive of the Institute of Neuropathology, University
Hospital RWTH Aachen, Germany, for muscle biopsies
containing TAs. A total of 15,412 muscle biopsies
obtained within the period from 1981 to 2011 were
analyzed for the search terms “tubular” and/or
“aggregates”. In our study, we included biopsies of
individuals who showed characteristic features of TAs at
the light microscopic or EM level according to Cameron
and colleagues (Cameron et al., 1992). Additional
muscle biopsies showing TAs were provided by the
Laboratory of Ultrastructural Neuropathology, Institute
Born-Bunge, University of Antwerp, Antwerp, Belgium
(20 biopsies), the Department of Neurology, University
Hospital Gent, Gent, Belgium (3 biopsies) and the
Institute for Neurological Research, FLENI, Buenos
Aires, Argentina (1 biopsy). Studies on family 1 (Fig. 1;
Martin et al., 1997) and family 2 (Fig. 1; Müller et al.,
2001) have been published previously. Diagnostic open
skeletal muscle biopsies were performed. The muscles
that were used for biopsy are indicated in Table 1. This
study was approved by the ethical committees of the
different cooperating centers and was conducted
according to the Declaration of Helsinki. 
Patients, clinical and paraclinical data
For all patients included in the present study, we
retrospectively collected information about the age and
symptoms at onset, presence of weakness, periodic
paralysis, myalgia, fatigability, cramps, stiffness,
contractures and myoglobinuria. Medical history and
drug use were considered, as well as the family history.
A general clinical and neurological examination was
performed. We also evaluated available information
about neurophysiological results (EMG/NCV/repetitive
nerve stimulation), imaging (muscle/brain), laboratory
values (CK/lactate), cardiologic data (ECG/echo-
cardiography/Holter-ECG), respiratory tests (lung
function/vital capacity), and diagnostics on tissue
samples.
Light microscopy and enzyme histochemistry
Muscle biopsy specimens were processed using
standard histological techniques (Dubowitz and Sewry,
2007). For histological studies, 10Ìm thick frozen
sections of unfixed material were stained using the
following reactions: hematoxylin eosin (HE), modified
Gomori’s trichrome (GT), periodic acid Schiff (PAS),
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oil-red-O (ORO), adenylate deaminase (AMPD),
NADH-tetrazolium reductase (NADH-TR), succinate
dehydrogenase (SDH), cytochrome oxidase (COX) and
adenosine triphosphatase (ATPase) at pH 9.4, 4.6 and
4.2. We reviewed all available reactions of the biopsies
for features of TAs. The percentage of fibers containing
TAs and the size of the TAs was measured following
AMPD reaction using an Axioskop microscope (Carl
Zeiss AG, Oberkochen, Germany). The fiber type of
muscle fibers containing TAs was assessed using ATPase
reactions at pH 9.4, 4.6 and 4.2. Other features examined
were fiber type predominance, myopathic and
neurogenic changes, and the presence of necrotic and
regenerating fibers, vacuoles, ragged red fibers (in GT
staining) and COX-negative/SDH-positive fibers.
Immunohistochemistry
In 6 biopsies (1.I.1, 1.II.1, 1.III.1, 1004, 1017, 1018;
Table 1; Fig. 1), we additionally evaluated the immuno-
histochemistry of the TAs. Normal, control samples were
included in the immunohistochemical analyses.
Antibodies included in the study were directed against:
alpha-actinin (mouse; monoclonal-anti-human, clone
BM-75.2;1:500; Sigma), alpha-B-crystallin (rabbit;
polyclonal-anti-human; Novocastra), alpha-dystroglycan
(mouse; ascites IgM,clone IIH6C4; 1:1000; Upstate
biotechnology), alpha-sarcoglycan (50kD; mouse; 1:200;
Dr. K. Campbell), alpha-tubulin (mouse; 1:1000;
Sigma), Alzheimer precursor protein, 22c11 (mouse;
1:10; Boehringer), ApoE (goat; 1:2000; Leiden), beta-
amyloid-protein-sequence-2-43,A4 (rabbit; 1:500;
Dr.K.Beyreuther), beta-dystroglycan (43kD; mouse;
1:200; Novocastra), caveolin-3 (goat; 1:1000;
SantaCruz), desmin (mouse; 1:200; Dakopatts),
developmental myosin-heavy-chain (MHC-d;mouse;
1:50; Novocastra), dysferlin (mouse; 1:1000;
NovoCastra), dystrophin-1 (mouse; monoclonal-anti-
human-rod-domain; 1:5; Novocastra), dystrophin-2
(mouse; monoclonal-anti-human C-terminus; 1:5;
Novocastra), dystrophin-3 (mouse; monoclonal-anti-
human N-terminus; 1:100; Novocastra), dystrophin-
associated glycoprotein (43kD and 50kD) (mouse;
1:200; NovoCastra), emerin (mouse; 1:100; Novocastra),
fast MHC (MHC-f; mouse; 1:200; NovoCastra); HLA-
ABC (mouse; 1:200; Dakopatts), HLA-DR (mouse;
1:50; Dakopatts), laminin (mouse; anti-human; clone
4C7; 1:100; Dakopatts), merosin (mouse; monoclonal-
anti-human merosin 80kD; 1:2000; Chemicon + mouse;
monoclonal-anti-human merosin 300kD; Novocastra),
myosin (rabbit; monoclonal-anti-human fast-skeletal-
myosin,clone MY-32; 1:50; Sigma), myotilin (mouse;
1:1000; NovoCastra), nebulin (mouse; 1:800; Sigma),
sarcomeric actin (mouse; monoclonal-anti-human
muscle actin, HHF35; 1:1000; Dako), slow MHC
(MHC-s; mouse; 1:200; NovoCastra), spectrin (mouse;
1:500; Novocastra), SR-Ca2+-ATPase-1 (mouse; 1:500;
Novocastra), SR-Ca2+-ATPase-2 (mouse; 1:500;
Novocastra), tau AT-8 (mouse; 1:20,000; Innogenetics),
tau AT-120 (mouse; 1:5000; Innogenetics), telethonin
(goat; 1:1000; SantaCruz), tropomyosin (mouse; 1:400;
Sigma), troponin-T (mouse; 1:500; Amersham),
ubiquitin (rabbit; 1:500; Dakopatts), utrophin (mouse;
1:100; Dr. G.E. Morris), and vimentin (mouse; 1:200;
Dakopatts). The Novocastra antibodies are now
marketed by Leica and the Chemicon antibodies by
Millipore. Additionally, we have used in one biopsy with
SDH-positive large TAs an antibody against SDH (more
precisely against the IP subunit of complex II; mouse;
1:4; MitoSciences). For immunolabeling the 3,3’-
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Fig. 1. Pedigrees of familial
cases with TAs. Black boxes
indicate affected individuals
(clinical symptoms and/or CK
elevation). Question mark (?),
unknown clinical status. B,
Biopsy with TAs; b, biopsy
without TAs. The arrow points
to the index patients. Asterisks
indicate the biopsies of three
relatives that were additionally
included in the present study.
diaminobenzidine technique was used.
Ultrastructural studies
For EM, muscle samples were fixed in phosphate-
buffered 4% glutaraldehyde, osmicated in 1%
phosphate-buffered osmium tetroxide, dehydrated and
embedded in Epon. Semithin sections (1-2 µm) were
stained by paraphenylene diamine and methylene blue.
The ultrathin sections (95 nm) of at least one transverse
and one longitudinal block were incubated in the
contrast agents, uranyl acetate and lead citrate.
Electronmicrographs were taken using a CM10
transmission EM (Philips, Amsterdam, Netherlands)
with the integrated sheet-film camera. We evaluated
position, type and size of the TAs, further abnormalities
of the SR and of connected membranous systems, the
presence of honeycombs, mitochondrial abnormalities,
amount of glycogen and lipids, myofibrillar structure,
nuclear abnormalities and the presence of autophagic
vacuoles. 
Measurement of the TAs
We measured the surface area of the largest visible
TAs in transverse EM images using ImageJ 1.44p
software (Wanye Rasband, National Institutes of Health,
Bethesda, Maryland, USA) and in transverse light-
microscopic sections using the AxioCam camera (Carl
Zeiss AG, Oberkochen, Germany) and the AxioVision
software (Carl Zeiss AG, Oberkochen, Germany). The
largest surface area of both measurements was further
used. 
Classification of the tubular aggregates
We classified the TAs according to Cameron and co-
workers (Cameron et al., 1992) and to Pavlovicová and
colleagues (Pavlovicová et al., 2003). Cameron and
colleagues defined aggregates of tubules, each
approximately 70 nm in diameter with a smaller inner
tubule or microtubule-like structure (type I; Fig. 2B),
aggregates of tubules each measuring between 70 and
400 nm in diameter and containing moderately dense,
flocculent material (type II; Fig. 2E), and aggregates of
dilated tubules each mostly between 130 and 400 nm in
diameter and containing a number of microtubule-like
structures (type III; Fig. 2C, indicated with an asterisk). 
In addition to these three TA types, Pavlovicová et
al. (2003) defined TAs with filamentous tubules (FTTA;
Fig. 2F,G), corresponding to type IIa of Schröder and
Becker (Schröder and Becker, 1972), aggregates with
tubulofilamentous structures (TFTA; Fig. 2I,J) which
correspond to the novel type of TAs first described by
Müller et al. (Müller et al., 2001), vesicular membrane
collections (VMC, Fig. 2E), proliferated terminal
cisterns (PTCs) that can be sub-divided into regularly
(RPTC; Fig. 2K) or irregularly (IPTC; Fig. 2L) PTCs
that had been shown by Schröder et al. (Schröder and
Adams, 1968; Schröder and Becker, 1972). We also
screened the biopsies for vacuoles most likely derived
from SR and/or transverse tubuli (Shy et al., 1961;
Dubowitz and Sewry, 2007; Fig. 2H), and giant tubules
with a diameter of 200 to 250 nm (Schröder and Becker,
1972). Although sub-sarcolemmal membranous
structures (SMS; Gullotta and Helpap, 1975; Reske-
Nielsen et al., 1975; Fig. 2M) differ substantially from
TAs by origin and shape, we additionally screened the
biopsies for the presence of SMS.
Results
Frequency and size of TAs
In our muscle biopsy archive, which comprises
15,412 muscle biopsies, we identified 82 biopsies
belonging to 79 individuals (76 index patients, i.e.
unrelated patients) that contained TAs, corresponding to
a frequency of 0.5%. Additionally, we included 24
biopsies from 23 patients (17 index patients) with TAs
obtained from other centers. Thus, our study comprises
106 biopsies from 103 patients (93 index patients) in
total.
In each biopsy, we measured the size of the largest
TA at transverse sections (Fig. 3; Table 1: size listed for
myopathies with large TAs). An arbitrarily chosen cut-
off value of 125 µm2 for the TA surface area was used.
Even if a biopsy contained mostly small TAs and more
rarely large TAs, the size of the largest TA was measured
and if the surface area was above 125 µm2, the biopsy
was classified as myopathy with large TAs (example in
Fig. 4J). A TA surface area of at least 125 µm2 was
present in 29 biopsies, whereas in the other 77 biopsies
the size of the largest TA ranged from 0.1 to 124 µm2
(Fig. 3). In each transversely cut light microscopic
section with visible TAs, we counted on average 683
muscle fibers (range 194-1029) in a randomly selected
position to determine the percentage of muscle fibers
containing TAs. We found a large variability in
frequency of TAs ranging from 1 to 90% (Table 1:
frequency listed for myopathies with large TAs).
Sometimes a focal distribution of affected fibers was
noticed. There was no correlation between the size and
the frequency of TAs in the muscle biopsies, which
might be due to mixing data from various muscles that
differ in the prevalent fiber type. In a further study, we
explored in detail 33 biopsies belonging to 25 index
patients with TAs of at least 125 µm2. The muscle
biopsies of three patients (Fig. 1, asterisks) were
additionally included for further study because they were
related to one of the index patients. 
Light microscopic and enzyme histochemical features of
biopsies with TAs
The light microscopic features of the 33 biopsies
with TAs larger than 125 µm2 are summarized in the
Table 1. In all cases, TAs showed a positive reaction for
1044
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Table 1. Maximal surface area and electron-microscopic features in myopathies with large tubular aggregates.
Sarcoplasmic Reticulum Metabolism Other features
Tubular aggregates Additional features Mitochondria Myofibrils Nuclei
Ind. Muscle Max. Tub. 
surf. diamtr. Local. I II III Ptc Vac. SMS Hon. ↑ Crst. Swell. Incl. ↑ ↑ Dis- Z Abml.Int. Aut.
(µm2) (nm) cmb. No. abml. / deg. Glgn. Lip. Org. str. vac.
.
1.III.1 VL 2200 48-355 S, I, N ++ + + - + - ± - + - - - ± - - + + -
1.II.1 VL 3900 49-276 S, I, N ++ + + - ++ - + - - - - - - + - - + +
1.I.1 D 600 49-190 S, I, N ++ + + - + - + - + - ± - ± + - - + +
2.II.1 D 1600 55-235 S, I, N + - ++ rptc + + - - - - + - - - - + + -
ftta ftta iptc
2.II.2 NA 850 30-135 S, I, N + + ++ - ± - - - - ± - - - - - - ± -
tfta
2.III.1 NA - - - - - - rptc - - - - - - - - - - - - - -
2.I.1 NA - - - - - - iptc - + - - - + ± - ± + - + - -
3.II.1 VL 1700 S, I, N + + + - + - - - - ± - - - + - - + ±
ftta ftta
3.II.2 NA - - - - - - - - - - - + + - - - ± - ± - ±
4.II.1 G 287 >60 S, I + - + - ++ - + - + + + - - ++ + + + +
5.I.1 BB 3100 35 S, I, N + + - - ++ - - - - + - - - - - - ± -
6.II.1 NA 340 50; S + vmc - - - - - - - + - - - - - - - -
240-350
7.II.1 RF > 490 90-110 S, I, N - + - rptc + - - ± - - - - - - - + - -
iptc
8.I.1 Q - no EM
8.II.1 Q 125 no EM
9* TA 1650 61-290 S, I, N + + - - + - - - - - - - ++ - + + + -
9* NA no EM
15 BB 800 - - - - - - - + - - - ± - ± - - - + - -
19 Q 1250 80 S, I, N + ± ± - ++ - - - - - - - - - - - - -
22 NA 300 45-55 S, I, N + + - rptc + - - - - - ± - - - - + - -
ftta
32 Q 2250 120-200 S, I, N - + - - + + - - - ± - - - - - - + -
ftta
42 BB 2800 55 S, N + - - - - - - - - - - - ± + + - ± -
52 G 1300 90-200 S, I, N - + - - + - - - - - - - ± ± - - - -
66 TB 340 60 low S, I, N + - - - + - - - - + - - - - - - + -
70 BB 1500 50; S, I, N + + - - - - - - - + - - - - - - + -
30-170 vmc
75 NA 437 55 S, I, N + - - rptc + - - - - + - - - ± ± - + -
84 G 217 65 S, N + - - rptc - - - - - + ± - - - - - - -
89 VL 300 40-160 S, I, N + + - - - - - - ± + ± - - - - - - -
ftta vmc
1004 G 2500 48-114 S, I, N + + + - + - - - - - - - - - - - + -
1017* Q 2800 50-60; S, I, N + + ± - + - - - - - - - - - - - + -
33-220
1017* G 650 >50 S, I, N + ± + - + - - - - - - - - ± - - + -
2001 NA 1300 no EM
3001 BB 4900 90 S - + - - - - - - ± ± - - - ± - - - -
4001 D 360 50-200 S, I, N + + - - + - - - - ± - - - - - - - -
vmc
++, Feature considerably present; +, feature present; ±, feature present in part; -, feature absent; *, two biopsies performed in the indicated person.
Ind., number of the individual; muscle, name of the muscle used for biopsy; max. surf., surface area of the largest tubular aggregate in transversal
section; tub. diamtr., range of the diameter of the tubules; local., localization of the TAs; I / II / III, types of TAs; dil. trd., dilated triads; ptc, proliferated
terminal cisterns; Vac., vacuoles derived from the sarcoplasmic reticulum and/or from transverse tubules; SMS, subsarcolemmal membranous
structures; hon. cmb., honey combs; ↑No., increased number; crst. abnl., abnormalities of the cristae; swell. / deg., swelling / degeneration; incl.,
inclusions; ↑Glgn., increased amount of glycogen; ↑lip., increased amount of lipid droplets; disorg., disorganization; z str., z band streaming; abnl.,
abnormal; int., internal; aut. vac., autophagic vacuoles. AF, M. adductor femoris; BB, M. biceps brachii; D, M. deltoideus; G, M. gastrocnemius; NA, not
available; Q, M. quadriceps femoris; RF, M. rectus femoris; TB, M. triceps brachii; VL, M. vastus lateralis. S, subsarcolemmal; I, intermyofibrillar; N,
near nuclei; ftta, TAs with filamentous tubules; tfta, aggregates of tubulo-filamentous structures; rptc, regularly proliferated terminal cisterns; iptc,
irregularly proliferated terminal cisterns; vmc, vesicular membrane collections; no EM, no electron microscopy was performed on this biopsy. For
abbreviations see further in methods section.
AMPD and NADH-TR. Most TAs stained strongly with
the PAS reaction (22/26, 85%), but did not react with the
menadione staining. The enzyme-histochemical
reactions in biopsies with small TAs did not differ from
the biopsies with large TAs. Interestingly, in the three
biopsies of family 1 and in the biopsies of 6 index
patients (Table 1 and Fig. 1: 1.I.1, 1.II.1, 1.III.1; 5.I.1, 3,
19, 70, 1004, 1017), the TAs reacted strongly with SDH
(Fig. 4H). In contrast, in the other patients as well as in
the cases with small TAs (n=77), TAs did not react with
SDH. For further results on SDH we refer to the next
section on immunohistochemical features.
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Fig. 2. Ultrastructural
spectrum of TAs. A. A
muscle fiber with a roundly
configurated TA showing a
surface area of 165µm2
(patient 1.II.1; Table 1)
located between myofibrils
in a transversely cut fiber.
B. Type I tubules, each
containing one smaller
tubule. C. Type I and type
III tubules (indicated by
asterisks) are shown in the
biopsy of patient 1004
(Table 1). D. Type I tubules
and some small
mitochondria (patient 3.II.2;
Table 1). E. Transversely
cut type II tubules arranged
in a hexagonal pattern,
some longitudinally cut
tubuli and VMCs, indicated
with an asterisk (patient 70,
Table 1). F. FTTA with type
I tubules. G. FTTA with type
II tubules. H. large vacuoles
most likely originating from
transverse tubules (+) near
a TA (patient 5.I.1, Table
1). I. TFTA, the novel type
of TAs (patient 2.II.1, Table
1). J. TFTA in longitudinal
view, showing the presence
of multiple inner tubular
structures (arrowhead).
Glycogen granules are
more electrondense and
located inbetween the TAs
(arrow). K. RPTC. L. IPTC.
Subsarcolemmal
membranous structures
(SMS) are shown in M.
Abbreviations: TA, tubular
aggregate; VMC, vesicular
membrane collections;
FTTA, TAs with filamentous
tubules; SR, sarcoplasmic
reticulum; TFTA,
tubulofilamentous TAs;
RPTC, regularly proliferated
terminal cisterns; IPTC,
irregularly proliferated
terminal cisterns; SMS,
subsarcolemmal
membranous structure (for
further description see
methods section). Scale
bars: 1 µm.
In most biopsies, TAs were present in sub-
sarcolemmal regions. In some cases TAs comprised
large rounded areas within the muscle fibers, and in
others TAs presented as multiple, smaller structures,
scattered across the muscle fibers (Fig. 4K). In 10 of 22
biopsies, TAs were present in both type 1 and type 2
fibers, and half of these biopsies belonged to cases with
a family history. Nevertheless, the TAs were always
more frequent and/or larger in type 2 fibers. In contrast,
in the group with small TAs (77 biopsies), which were
visible by light microscopy, TAs were exclusively found
in type 2 fibers. Pathological predominance of type 1
fibers was present in 4/23 biopsies (17%) and
pathological predominance of type 2 fibers was present
in 1/23 biopsies (4%). Most biopsies with TAs showed
myopathic changes (17/26, 65%), some showed
neurogenic alterations (8/26, 31%), necrotic and/or
regenerative fibers (4/25, 16%) or vacuoles (2/26, 8%).
Immunohistochemical features of biopsies with TAs
In six biopsies with large TAs, we additionally
performed immunohistochemical reactions with
antibodies directed against different components of the
muscle fiber (Fig. 5). Immunohistochemical data on
biopsies with small TAs were not available. TAs showed
a positive immunoreactivity for antibodies directed
against SERCA-1 (Fig. 5B). In addition, the three
biopsies of family 1 revealed SERCA-2 immunoreactive
TAs in both type 1 and type 2 fibers. Thus, labeling of
TAs by SERCA was mostly, but not always, of the same
isoform as in the rest of the fiber. In the biopsies of
patients 1004 and 1017, emerin-positive TAs were noted
(Fig. 5F). Single biopsies also showed TAs to be
immuno-positive for tau (patient 1.I.1), HLA-ABC
(patient 1.II.1), ubiquitin (patient 1017, Fig. 5L), alpha-
dystroglycan and telethonin (patient 1004). In the biopsy
of patient 1.III.1, TAs were immuno-positive for
sarcomeric actin.
In order to exclude the possibility of an unspecific
SDH reaction in the SDH-positive TAs, an antibody
against SDH (more precisely against the IP sub-unit of
complex II) was used in one biopsy with SDH-positive
large TAs. The TAs showed a positive reaction for the
anti-SDH/IP-antibody, indicating the presence of at least
this complex II component in the TAs.
TAs were immuno-negative for alpha-actinin and
alphaB-crystallin, ApoE, APP (22C11), AT8, caveolin-3,
desmin, dysferlin, dystrophin-1, dystrophin-2,
dystrophin 3, dystrophin-associated glycoprotein (43kD
and 50kD), fast skeletal myosin, HLA-DR, laminin,
merosin, MHC-d, MHC-f, MHC-s, myotilin, nebulin,
spectrin, tropomyosin, troponin-T, tubulin, utrophin,
vimentin.. The different components of the muscle fibers
showed an otherwise normal immunoreactivity for the
range of antibodies used. 
Ultrastructural spectrum of TAs
Detailed ultrastructural analysis of the sub-group
with large TAs is presented in Table 1. We found a large
variability of ultrastructural changes (Fig. 2). In the
group with large TAs, we found 5/30 biopsies (17%)
exclusively showing tubules containing an inner central
tubule (type I; Fig. 2B) and 4/30 (13%) exclusively
presenting tubules with content of low electron density
(type II; Fig. 2E). No biopsy showed exclusive
occurrence of an outer tubule with at least two inner
tubules (type III; Fig. 2C, asterisks). In 57% of all
biopsies, more than one type of TA was present: type I
and II in 6/30 biopsies (20%), type I and III in 2/30
biopsies (7%) and all three types in 9/30 biopsies (30%).
Interestingly, in one family (family 2, Fig. 1), type III
TAs with up to 38 tubules were observed (TFTA, Fig. 2I,
2J; Table 1). We additionally observed FTTA in 5/30
biopsies (17%; Fig. 2F, 2G), VMC in 4/30 biopsies
(13%; Fig. 2E) and PTC in 7/30 biopsies (23%; Fig. 2K,
2L). Vacuoles derived from SR and/or from transverse
tubuli could be seen in 20/30 biopsies (67%; Fig. 2H).
SMS, which differ from rimmed vacuoles by the fact
that they do not contain debris, were found in 4/30
biopsies (13%; Fig. 2M). Furthermore, the presence of
SMS did not correspond to the presence of rimmed
vacuoles at the LM level. At the ultrastructural level, we
found no correlate for the SDH-positive reaction of TAs
observed in some biopsies, in particular no increase of
mitochondria number or of abnormal mitochondria could
be found.
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Fig. 3. Size distribution of TAs. Each dot represents the surface area
(µm2) of the largest TA in each muscle biopsy (n=102). The cut-off value
at 125 µm2 results in 29 biopsies with TAs of at least 125 µm2 in surface
area. The biopsies are arranged according to the size of the largest
TAs.
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Fig 4. Light microscopic and enzyme histochemical features of TAs. A-H. Serial sections of the first muscle biopsy (M. quadriceps) of patient 1017
(Table 1) with large, mostly rounded TAs. A. HE; B. GT; C. AMPD; D. ATPase at pH 4.2; E. ATPase at pH 4.6; F. ATPase at pH 9.4; G. NADH-TR; 
H. PAS. TAs show a positive reaction for AMPD, NADH, SDH (K) and PAS. In this biopsy most TAs are present in type 2b fibers, which are stained
intermediately in ATPase at pH 4.6 and dark in ATPase at pH 9.4 (one exemplary fiber marked with asterisk). Less frequently, TAs can be seen inside
type 2a fibers (arrowhead in GT, ATPase at pH 4.6 and 9.2). Rarely, TAs are localized inside type 1 fibers (arrow in HE, ATPase at pH 4.2 and 4.6). 
I. HE: Longitudinal section from the same biopsy, showing a large TA including several myonuclei. J. AMPD: Biopsy from the same patient, retrieved
one year later (M. gastrocnemius). Here, TAs are multiple, smaller structures and scattered across the muscle fibers. K. SDH and L. anti-SDH-antibody
in biopsy of patient 1.II.1 (Table 1) with TAs in type 2 fibers showing positive reaction for SDH and positive immunoreactivity for an anti-SDH-antibody.
Scale bars: 100 µm.
Clinical findings
The median age at onset was 37.6 years (range 3-78)
in the group with large TAs and 36.4 years (range 2-73)
in the group with small TAs. The average disease
duration at the time of biopsy was 3.9 years in the first
group (range 0-40) and 4.2 years in the second group (0-
52). In the group with large TAs, 90% of the index
patients were male, compared to 71% in the other group.
The symptoms of patients with large and small TAs are
summarized in Table 2. The most frequent symptom in
both groups was limb muscle weakness, followed by
myalgia, fatigability, muscle cramps and stiffness. No
significant differences in clinical presentation were
found between the two groups.
In 8 out of 25 index patients (32%) with large TAs, a
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Fig. 5. Immunohistochemical features of large TAs A-J. Serial sections from the first biopsy (M. quadriceps) of patient 1017 (Table 1). K, L. Serial
sections from the same biopsy of patient 1017. A. HE: large TAs are mainly located underneath the sarcolemma. B. SERCA-1: TAs show a stronger
immunoreactivity than the SR of type 2 fibers. C. SERCA-2: no staining of the TAs. D. Dystrophin-3: TAs are not stained, while the sarcolemmal
immunoreaction is normal. E. Desmin: no staining of the TAs. F. Emerin: positive immunoreactivity of the TAs and the nuclear membranes. G. Human
fast skeletal myosin: TAs are unstained. H. MHC-f: TAs are unstained for the myosin heavy chain of type 2 fibers, while their sarcoplasm shows a
positive immunoreactivity. I. Actin: the TAs are not stained for actin. J. Bigtau-404: no immunoreactivity of the TAs. K. Tubulin: no immunoreactivity of
the TAs. L. Ubiquitin: positive immunoreactivity of the TAs for ubiquitin. Scale bars: 100 µm.
family history of clinical symptoms and/or increased
serum-CK was present. There was no known
consanguinity. In patients 3.II.1 and 3.II.2 (Fig. 1)
hyperornithinemia with gyrate atrophy of the choroids
and retina was diagnosed. TAs of skeletal muscle fibers
have been found earlier in this disease (Sipilä et al.,
1979). In our study group with large TAs, we did not
find another associated disorder or possible cause that
could explain the presence of TAs in muscle fibers. In
contrast, in the group with small TAs (77 biopsies), we
noticed another associated disease in 50 cases (65%;
summarized in Table 3) and a family history in only 4
patients (5%). The presence of small TAs in the muscle
biopsy in our cohort is most frequently associated with
mitochondrial disorder (14 patients or 18%),
polyneuropathy or toxic drug-induced myopathy (Table
3). In the group of patients with small TAs associated
with mitochondrial disorder, a genetic defect was
identified in one patient (4977 bp deletion mtDNA). In
two other patients, mutations responsible for MERRF,
MELAS and NARP were excluded. In the remaining
patients, molecular genetic analyses were not performed
or the data were not available. The diagnosis of
mitochondrial disorder was then based upon clinical
features and muscle biopsy findings. We found no
correlation between the ultrastructural data and clinical
presentations in either sub-group, or between the
morphological features of TAs and the associated
disorder in the sub-group with small TAs. 
Discussion
We studied the histopathological and clinical
spectrum in a large cohort of patients with TAs in their
muscle biopsy. Based on the size of TAs, we defined two
sub-groups: (1) myopathies with large TAs,
characterized by the presence of TAs in type 2 fibers and
sometimes also in type 1 fibers, the absence of another
associated disorder, and a family history in half of the
cases, and (2) myopathies with small TAs, presenting
TAs exclusively in type 2 fibers, the presence of another
associated disease in many patients and mostly no family
history. No significant differences in clinical
presentation, in age at onset or in disease duration at the
time of biopsy were found between the two groups. We
also observed a large variability in ultrastructural
changes.
In our study, TAs occurred in 0.5% of the muscle
biopsies from our archive (15,412 biopsies). Biopsies
with small TAs exclusively visible by means of EM are
included in this number. According to published data,
the prevalence of TAs in muscle biopsies ranges from
0.2 to 1.6%: TAs were found in 1.6% (n=1,500, Engel et
al., 1970), 0.6% (n=3,000, Niakan et al., 1985), 1.0%
(n=1,500, Rosenberg et al., 1985), 0.2% (n=7,000, Oh et
al., 2006) and 0.24% (n=7,441, Ghosh et al., 2010) of all
included muscle biopsies.
We used the size of the TAs, measured by the
surface area of the largest TA in transverse sections, as a
criterion to further define and characterize these
myopathies. We chose an arbitrary cut-off value of 125
µm2. In 0.19% of all biopsies, we found large TAs of at
least 125 µm2 in surface area. This sub-group might
correspond to the so-called “primary TA myopathies
(TAM)” (Dobkin and Verity, 1978; Rohkamm et al.,
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Table 2. Symptoms in patients with myopathies with large and small
TAs.
Symptoms Large TAs Small TAs All
Limb weakness 16 (55%) 39 (51%) 52%
Myalgia 12 (41%) 34 (44%) 43%
Fatigability 8 (28%) 25 (32%) 31%
Muscle cramps 7 (24%) 13 (17%) 19%
Muscle stiffness 4 (14%) 8 (10%) 11%
Table 3. Associated diseases and conditions in cases with small tubular aggregates.
Associated disease Number of biopsies (n = 76) References
Mitochondrial disorder 14 (18 %) Garrard et al., 2002; Novotová et al ., 2002
Polyneuropathy 9 (12 %) Fardeau et al., 1979; Niakan et al., 1985
Toxic / Drug-induced myopathy 5 (7 %) Engel et al., 1970; Fardeau et al., 1979
Familial malignant hyperthermia 4 (5 %) Gullotta and Helpap, 1975; Reske-Nielsen et al., 1975
Myotonic myopathy 4 (5 %) Schröder and Becker, 1972
Alcohol-induced myopathy 4 (5 %) Gullotta and Helpap, 1975; del Villar Negro et al., 1982
Hypokalemic periodic paralyses 2 (3 %) Engel et al., 1970; Jurkat-Rott et al., 2000
Glycogenosis 2 (3 %) Vissing et al., 1999; Oh et al., 2006
CADASIL 1 (1 %) Schröder et al., 2005
Diabetic amyotrophy 1 (1 %) Chokroverty et al., 1977
(Paraneoplastic) dermatomyositis 1 (1 %) Rosenberg et al., 1985
Polymyositis 1 (1 %) Grunnet et al., 1988
(Other) metabolic myopathy 1 (1 %) -
M. Fabry 1 (1 %) -
Without obvious association 26 (34 %) -
1983; Pierobon-Bormioli, 1985; Martin et al., 1997;
Müller et al., 2001; Vielhaber et al., 2001; Jacques et al.,
2002; Shahrizaila et al., 2004; Ghosh et al., 2010), since
many of these cases are familial and there is no other
associated disease that might explain the morphological
findings, and TAs are a prominent feature in the biopsy
occuring in both type 1 and type 2 fibers. The sub-group
showing TAs with a surface area smaller than 125 µm2
might have developed TAs as a “secondary and non-
specific phenomenon” (Chevessier et al., 2005) that is
associated with another disease that is non-familial and
is restricted to type 2 fibers (Engel et al., 1970;
Dubowitz and Sewry, 2007). We also considered other
possible morphological criteria for primary TAM, such
as the frequency of muscle fibers containing TAs.
However, the frequency varied largely from 1- 90%, and
no correlation between the maximal surface area and the
frequency of TAs was found. Possible bias and
limitations in using these morphological criteria are
muscle selection for biopsy, and a sometimes unequal
distribution of TAs within the same biopsy (Dubowitz
and Sewry, 2007).
The presence of TAs in inbred mice is restricted to
males (Agbulut et al., 2000; Chevessier et al., 2005). In
humans, a sex-dependent prevalence of TAs has also
been observed (Engel et al., 1970; Niakan et al., 1985;
Rosenberg et al., 1985; Müller et al., 2001; Vielhaber et
al., 2001; Oh et al., 2006; Ghosh et al., 2010). In our
study, 90% of the index patients in the group with large
TAs and 71% of the patients in the group with small TAs
were male, corresponding to previous observations. TAs
are usually seen in type 2 fibers (Engel et al., 1970;
Dubowitz and Sewry, 2007). However, they can also
occur in type 1 fibers in primary TAM (Dobkin and
Verity, 1978; Rohkamm et al., 1983; Pierobon-Bormioli,
1985; Martin et al., 1997; Jacques et al., 2002;
Shahrizaila et al., 2004; Ghosh et al., 2010). In our group
with large TAs, we found some type 1 fibers containing
TAs, but in the other biopsies there was predominance of
TAs in type 2 fibers. A possible explanation is the
“abundance of SR” in type 2 fibers compared to type 1
fibers (Shahrizaila et al., 2004). Furthermore, specific
properties of metabolism, including differences in
mitochondrial occurrence (Ogata and Yamasaki, 1997;
Novotová et al., 2002), calcium homeostasis and protein
expression might contribute to the TA formation in type
2 fibers. 
At the EM level, a large variability in ultrastructural
features was found in the group with large TAs. We
found type I and type II tubules and the combination of
these types in the majority of biopsies (50%, n=30).
Type III tubules were most frequently found in
combination with type I and type II tubules (30%), or
rarely only in combination with type I tubules (7%). In
contrast, type III tubules were never seen as a sole
feature, or in combination with type II tubules.
Interestingly, in one family (family 2), TFTAs with up to
38 tubules were observed. Assuming gradual in vivo TA
formation (Engel et al., 1970) type III tubules could
represent a late stage of this process. The hypothesis of
gradual composition is supported by biopsies of the
extensor digitorum longus muscle (EDL) of mice of
different ages (Boncompagni et al., 2012). In contrast,
Schiaffino et al. (Schiaffino et al., 1977) showed the in
vitro formation of TAs within hours induced by anoxia
in the EDL of rats and they concluded that a
rearrangement and/or aggregation of existing SR
structures is more likely than an active neoformation of
TAs. 
A comprehensive classification of tubular and
cisternal systems of the muscle fiber was suggested by
Schröder and Becker in 1972 (Schröder and Becker,
1972). They described tubules of 50 to 80 nm in
diameter containing inner tubules (type Ib) and tubules
of 40 to 50 nm in diameter without inner tubules (type
Ic). These types have later been correlated with the type
I and II tubules of Cameron and coworkers (Cameron et
al., 1992; Müller et al., 2001). Schröder and Becker also
characterized regularly and irregularly PTC of 80 to
90nm in diameter (type Ia) and giant tubules (type IIb;
Schröder and Becker, 1972). We found FTTA and PTC
each in about 20% of the biopsies with large TAs. VMC
(13%) and TFTA (7%) were seen less frequently. Giant
tubules were not present in the biopsies included in the
present study.
The formation of TAs from the SR is supported by
many studies (Schröder and Adams, 1968; Engel et al.,
1970; Salviati et al., 1985; Martin et al., 1997;
Chevessier et al., 2005). Furthermore, some data support
the presence of mitochondria in TAs (Lewis et al., 1971;
Rosenberg et al., 1985; Meijer, 1988; Vielhaber et al.,
2001; Novotová et al., 2002). Activity of mitochondrial
enzymes has been noted. Rosenberg et al. found TAs
staining “reddish-brown” for SDH (Rosenberg et al.,
1985). COX-positive TAs were described by Lewis et al.
(Lewis et al., 1971). Meijer (1988) performed extensive
histochemical adsorption studies on muscle sections
containing TAs. High affinities of the TAs for NADH-
TR and COX could be recognized. However, other
mitochondrial enzymes showed a low affinity for TAs or
had no affinity, such as SDH. Furthermore, the presence
of the bc1-protein, which is an integral part of the inner
mitochondrial membrane, could be shown in TAs by
immunogold-labeling; the study was conducted in mice
with invalidated cytosolic and mitochondrial creatin
kinase (Novotová et al., 2002). In our study, in the three
biopsies of family 1 and in 6 additional unrelated
individuals, the TAs stained strongly with SDH, whereas
the other cases were negative. For the mixed results on
mitochondrial participation in TA formation, different
possible explanations exist. Firstly, there may be
different mechanisms of TA emergence, with some TAs
partly assembling from mitochondria (Meijer, 1988).
Secondly, a diffusion of mitochondrial enzymes into TAs
might take place, particularly of NADH-TR because of
its high affinity to TAs (Meijer, 1988). In contrast, COX-
positive TAs are seen very rarely (Lewis et al., 1971), in
spite of their high COX-affinity (Meijer, 1988). Thirdly,
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an unspecific reaction could take place and might be
misinterpreted as mitochondrial enzymatic activity. Such
an unspecific reaction has for example been shown for
enzyme assays based on tetranitroblue tetrazolium
(TNBT), particularly in AMPD and NADH-TR assays
(Fuchs and Wohlrab, 1967; Higuchi et al., 1987).
However, we have excluded the possibility of an
unspecific reaction by confirming our results using an
anti-SDH-antibody. Further studies will be necessary to
clarify this issue.
Several hypotheses about the function of TAs in
muscle fibers have been suggested, such as an adaptive
response of the muscle fibers to increased intracellular
calcium flux or a functional link with mitochondrial
dysfunction and abnormal intracellular energy
metabolism (Salviati et al., 1985; Steeghs et al., 1997;
Vielhaber et al., 2001). Heat-shock proteins have also
been suggested to play a role in the formation of TAs
(Martin et al., 1991). We tested the TAs for alpha-B-
crystallin as a heat-shock protein, but no
immunoreactivity was revealed. Furthermore, we found
expression of proteins that are not directly related to the
SR, such as dysferlin and emerin, as has been previously
reported in TAs (Ikezoe et al., 2003; Vita et al., 2003;
Manta et al., 2004). Ikezoe et al. suggested that dysferlin
could be expressed in response to disturbed sarcoplasmic
Ca2+-homeostasis (Ikezoe et al., 2003). Manta and
coworkers (Manta et al., 2004) described emerin-
positive TAs and proposed a possible mutation in emerin
leading to its mislocalization into the SR membrane
instead of the inner nuclear membrane. We also found
ubiquitin- and tau positive TAs, as previously shown by
Luan et al. (2009). Ubiquitin in TAs probably plays a
role in labeling accumulated proteins for degradation
(Luan et al., 2009). The accumulation of tau shows a
possible link to neurodegenerative diseases, as has been
recently suggested by Schiaffino (2012). He proposed
that TAs are a special type of protein aggregates
comparable to protein aggregates in neurodegenerative
diseases. Thus, the pathophysiology of TAs seems to be
diverse, and further insights might come from future
studies in genetically confirmed families with tubular
aggregate myopathy.
As a practical clinico-pathological guideline, one
should think of myopathy with TAs as a possible
diagnosis in a patient presenting with limb muscle
weakness, myalgia, fatigability, muscle cramps and/or
stiffness. A muscle biopsy and AMPD and/or NADH-
TR reaction should be performed, which would reveal
positively stained TAs. The AMPD-reaction stains TAs,
whereas the NADH-TR reaction stains TAs and
mitochondria. In addition, electron microscopic studies
are recommended. Furthermore, it would be interesting
to measure the size of the TAs in transverse sections of
muscle fibers, using a cut-off value of 125 µm2 to
distinguish between large TAs (≥125 µm2) and small
TAs (<125 µm2). The distinction between myopathies
with large TAs and myopathies with small TAs is
important, because the myopathies with large TAs most
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probably have a primary genetic cause, indicated by
their familial occurrence without other associated
disorders. This group of myopathies with large TAs will
in further studies be used for the identification of
causative genes using novel genetic techniques. Finding
the underlying genes in this myopathy will have clinical
relevance and might lead to a better understanding of
underlying pathomechanisms. In myopathies with small
TAs, another associated disease is present in most cases,
and a family history is unlikely. The most frequent
associated disorder in muscle biopsies showing small
TAs that should be looked for is a mitochondrial disease.
To date, no curative treatment is available for
myopathies with TAs. 
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